MaxCyte Inc (MaxCyte) is a commercial cell engineering company that provides platform technologies to advance the discovery, development, and commercialization of cell therapeutics, including cell and gene therapies. MaxCyte has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. The company's customers include commercial cell therapy drug and biologic developers, biopharmaceutical companies, and academic and government research institutions.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

MaxCyte has undertaken significant R&D initiatives focused on advancing its proprietary Flow Electroporation technology and developing the ExPERT platform to support the discovery, development, and commercialization of next-generation cell therapeutics. The company is committed to enhancing its existing products and developing new products for current and new markets. MaxCyte’s R&D efforts are aligned with its strategy to maintain a competitive position in the cell engineering market. Its R&D units are divided into two teams: applications and instrumentation. The applications team is responsible for developing data on key applications, improving cell handling and culture approaches, designing and enhancing electroporation protocols, and performing product testing and quality assurance activities. The instrumentation engineering team focuses on developing and improving electroporation instruments and PAs to meet a wide range of customer needs from research to commercialization in a GMP environment. The company has one R&D center located in Maryland. It holds more than 200 granted U.S. and foreign patents and has over 100 pending patent applications worldwide. The company does not have its own pipeline of therapeutic candidates but focuses on developing its cell engineering offerings, including the ExPERT platform. There is no specific information provided about major technology alliances. As of December 31, 2025, the company’s patent portfolio consisted of more than 200 granted US and foreign patents, including in Australia, Canada, Japan, China, South Korea, and certain countries in Europe, and more than 100 pending patent applications worldwide. In FY2025, the company spent US$20.8 million on its R&D activities, which as a percentage of revenue stood at 63%.